34 results
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
23 May 24
Other Events
5:41pm
vaccine that targets cancers that are driven by mutations in the mKRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
15 May 24
Results of Operations and Financial Condition
4:34pm
that targets cancers that are driven by mutations in the mKRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
5 Apr 24
Other Events
4:33pm
, is a structurally novel investigational AMP cancer vaccine that targets cancers that are driven by mutations in the mKRAS-gene—a prevalent driver
8-K
EX-99.2
o3qlc p51n9oc1l
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
8-K
EX-99.2
b28atg
27 Sep 23
Other Events
5:41pm
8-K
EX-99.1
sw7hf628h6zmiqg jn
5 Jun 23
Other Events
8:00am
8-K
EX-99.3
7ifik6ilf3 oy
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
8-K
EX-99.4
c18m 3u5acr7e5k
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
424B3
tndgq2oq9rsb
28 Apr 23
Prospectus supplement
4:07pm
8-K
EX-99.2
wyr9k61n7hbgb
27 Apr 23
Other Events
5:20pm
CORRESP
9qbh01 hk3hl9
13 Apr 23
Correspondence with SEC
12:00am
S-4/A
EX-10.32
ikgw588lf9e7j
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
S-4/A
ides572v oaegj
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm